Production of “biological carriers” for...

Details Production of “biological carriers” for... Production of “biological carriers” for...

2002-02-12

2009-08-25

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C435S069100, C435S069300, C435S235100, C435S236000, C435S239000, C424S184100, C424S208100

Reexamination Certificate

active

07579007

ABSTRACT:
This application provides a method to form non-infectious Biological Carrier that may be used to deliver signals to cells either in vitro or in vivo. The Biological Carriers are inactivated virus particles that have been specifically modified to give biological properties different from the virus particles deriving from an unmodified host cell that (i) expresses at least one co-stimulatory molecule and (iia) at least one antigen that can initiate an immune response, and/or (iib) express surface molecules that suppress viral replication.

REFERENCES:
patent: 5306631 (1994-04-01), Harrison et al.
patent: 5855891 (1999-01-01), Lowy et al.
patent: 6149906 (2000-11-01), Mosca
patent: WO 99/15199 (1999-04-01), None
Cantin et al., “The Amount of Host HLA-DR Proteins Acquired by HIV-1 Is Virus Strain- and Cell Type-Specific,” Virology, vol. 218 No. 2, pp. 372-381 (Apr. 1996).
Esser et al., “Differential Incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and Major Histocompatibility Complex Class I and II Molecules into Human Immunodeficiency Virus Type 1 Virions and Microvesicles: Implications for Viral Pathogenesis and Immune Regulation,” Journal of Virology, vol. 75 No. 13, pp. 6173-6182 (Jul. 2001).
Oertli et al., “Artificial antigen-presenting cells engineered by recombinant vaccinia viruses expressing antigen, MHC class II, and costimulatory molecules elicit proliferation of CD4+ lymphocytes in vitro ,” Clincal and Experimental Immunology, vol. 110 No. 1, pp. 144-149 (Sep. 1997).
Roy et al., “HIV type 1 can act as an APC upon acquisition from the host cell of peptide-loaded HLA-DR and CD86 molecules,” Journal of Immunology, vol. 174 No. 8, pp. 4779-4788 (Apr. 2005).
Rossio et al., “HLA class II on HIV particles is functional in superantigen presentation to human T cells: implications for HIV pathogenesis”, AIDS Research and Human Retroviruses, vol. 11 No. 12, pp. 1433-1439 (Dec. 1995).
Tremblay et al., “The acquisition of host-encoded proteins by nascent HIV-I,” Immunology Today, vol. 19, pp. 345-350 (1998).
Giguère et al., “Insertion of Host-Derived Costimulatory Molecules CD80 (B7.1) and CD86 (B7.2) into Human Immunodeficiency Virus Type 1 Affects the Virus Life Cycle,” Journal of Virology, vol. 78 No. 12, pp. 6222-6232 (Jun. 2004).
Chang, Efficient amplification of melanoma-specific CD8+ T cells using artificial antigen presenting complex, Experimental and Molecular Medicine, vol. 38 No. 6, pp. 591-598 (2006).
Derdak et al., “Direct stimulation of T lymphocytes by immunosomes: Virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules,” Proceedings of the National Academy of Sciences, USA, vol. 103 No. 35, pp. 13144-13149 (2006).
Kim et al., “The ABCs of artificial antigen presentation,” Nature Biotechnology, vol. 22, pp. 403-410 (2004).
Moody et al., “Anatomy of CD1-Lipid antigen complexes,” Nature Reviews, Immunology, vol. 5 No. 5, pp. 387-399 (May 2005).
Zajonc et al., “CD1 mediated T cell recognition of glycolipids,” Current Opinion in Structural Biology, vol. 17, Issue 5, Oct. 2007, pp. 521-529.

Affiliated with

Also associated with

Rating

Production of “biological carriers” for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Production of “biological carriers” for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production of “biological carriers” for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4106734